Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction

Xilifu,Dilidaer; Abudula,Abulizi; Rehemu,Nijiati; Zhao,Long; Zhou,Xinrong; Zhang,Xiangyang

doi:10.3892/etm.2014.2027

Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction

Authors:
- Dilidaer Xilifu
- Abulizi Abudula
- Nijiati Rehemu
- Long Zhao
- Xinrong Zhou
- Xiangyang Zhang
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital, Xinjiang Medical University, Ürümqi, Xinjiang 830011, P.R. China, Xinjiang Key Laboratory of Molecular Biology and Endemic Diseases, Xinjiang Medical University, Ürümqi, Xinjiang 830011, P.R. China, Department of Pathology, School of Basic Medicine, Xinjiang Medical University, Ürümqi, Xinjiang 830011, P.R. China
Published online on: October 15, 2014 https://doi.org/10.3892/etm.2014.2027
Pages: 1683-1688

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endothelial dysfunction plays a key role in the development of cardiovascular diseases, renal injuries and hypertension induced by hyperuricemia. Therapies targeting uric acid (UA) may be beneficial in cardiovascular diseases. In the present study, the effect of rosuvastatin, a 3‑hydroxy‑3‑methylglutaryl coenzyme A reductase inhibitor, was investigated to determine whether rosuvastatin improves endothelial dysfunction via the endothelial nitric oxide (NO) pathway and delays the pathogenesis of endothelial dysfunction in hyperuricemic rats. A total of 72 Sprague‑Dawley rats (age, 8 weeks) were randomly divided into six groups (12 rats per group), including the control, model, 2.5 mg/kg/day rosuvastatin, 5 mg/kg/day rosuvastatin, 10 mg/kg/day rosuvastatin and 53.57 mg/kg/day allopurinol groups. The model, rosuvastatin and allopurinol rats were subjected to hyperuricemia, induced by the administration of yeast extract powder (21 g/kg/day) and oxonic acid potassium salt (200 mg/kg/day). The hyperuricemic rats were treated with 2.5, 5.0 or 10.0 mg/kg/day rosuvastatin orally for six weeks, while rats treated with allopurinol (53.57 mg/kg/day) were used as a positive control. The serum levels of NO and the gene expression levels of endothelial NO synthase in the aortic tissue increased, whereas the serum levels of UA, endothelin‑1 and angiotensin II decreased in the hyperuricemic rats treated with rosuvastatin, particularly at a high rosuvastatin dose (10 mg/kg/day). In addition, the curative effect of the 10 mg/kg/day rosuvastatin group was evidently higher compared with the allopurinol group. Therefore, rosuvastatin may be a novel drug candidate for the treatment of hyperuricemia due to its endothelial protective properties.

View Figures

View References

1	Ghisi GL, Durieux A, Pinho R and Benetti M: Physical exercise and endothelial dysfunction. Arq Bras Cardiol. 95:e130–e137. 2010.(In English, Portuguese and Spanish).
2	Gao X, Martinez-Lemus LA and Zhang C: Endothelium-derived hyperpolarizing factor and diabetes. World J Cardiol. 3:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
3	Oelze M, Schuhmacher S and Daiber A: Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate. Exp Diabetes Res. 2010:2131762010. View Article : Google Scholar : PubMed/NCBI
4	Sandoo A, van Zanten JJ, Metsios GS, Carroll D and Kitas GD: The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J. 4:302–312. 2010.PubMed/NCBI
5	Franses JW, Baker AB, Chitalia VC and Edelman ER: Stromal endothelial cells directly influence cancer progression. Sci Transl Med. 3:66ra52011. View Article : Google Scholar : PubMed/NCBI
6	Barton M: Prevention and endothelial therapy of coronary artery disease. Curr Opin Pharmacol. 13:226–241. 2013. View Article : Google Scholar : PubMed/NCBI
7	Mount DB: The kidney in hyperuricemia and gout. Curr Opin Nephrol Hypertens. 22:216–223. 2013. View Article : Google Scholar : PubMed/NCBI
8	Bakris GL, Doghramji PP, Keenan RT and Silber SH: CaseBook challenges: Managing gout, hyperuricemia and comorbidities - dialogue with the experts. Am J Med. 127:S12014. View Article : Google Scholar : PubMed/NCBI
9	Sautner J, Gruber J, Herold M, Zwerina J and Leeb BF: Austrian 3e-recommendations for diagnosis and management of gout 2013. Wien Klin Wochenschr. 126:79–89. 2014.(In German).
10	Maruhashi T, Nakashima A, Soga J, et al: Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women. BMJ Open. 3:e0036592013. View Article : Google Scholar : PubMed/NCBI
11	Xu Y, Zhu J, Gao L, et al: Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS One. 8:e782062013. View Article : Google Scholar : PubMed/NCBI
12	Ndrepepa G, Cassese S, Braun S, et al: A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 23:1195–1201. 2013. View Article : Google Scholar : PubMed/NCBI
13	Fan Y and Chen YE: Combined therapeutic strategy to improve vascular endothelial function after implantation of sirolimus-eluting stents. Circ J. 75:1051–1052. 2011. View Article : Google Scholar : PubMed/NCBI
14	Ghaffari N, Ball C, Kennedy JA, Stafford I and Beltrame JF: Acute modulation of vasoconstrictor responses by pravastatin in small vessels. Circ J. 75:1506–1514. 2011. View Article : Google Scholar : PubMed/NCBI
15	Foody JM, Toth PP, Tomassini JE, et al: Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag. 9:719–727. 2013. View Article : Google Scholar : PubMed/NCBI
16	Maji D, Shaikh S, Solanki D and Gaurav K: Safety of statins. Indian J Endocrinol Metab. 17:636–646. 2013. View Article : Google Scholar
17	Kones R: Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease - a perspective. Drug Des Devel Ther. 4:383–413. 2010. View Article : Google Scholar : PubMed/NCBI
18	Savoia C, Sisalli MJ, Di Renzo G, Annunziato L and Scorziello A: Rosuvastatin-induced neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation. Int J Physiol Pathophysiol Pharmacol. 3:57–64. 2011.PubMed/NCBI
19	Chen GL, Zhang QL, Ma XQ and Xu SY: Hyperuricemia model induced by yeast in mice. Zhongguo Yao Li Xue Tong Bao. 19:467–469. 2003.(In Chinese).
20	Guide for the care and use of laboratory animals. 8th Edition. The National Academies Press; Washington, D.C, USA: pp. 11–35. 2011
21	Xilifu D, Zhao P, Song LJ, Rehemu N and Zhang XY: Development of secondary cardiovascular disease in hyperuricemia model rats induced by yeast extract combined with oteracil potassium. Zhongguo Zuzhi Gongcheng Yanjiu. 16:1994–1998. 2012.
22	Tomiyama H, Higashi Y, Takase B, et al: Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am J Hypertens. 24:770–774. 2011. View Article : Google Scholar : PubMed/NCBI
23	Hwa KS, Chung DM, Chung YC and Chun HK: Hypouricemic effects of anthocyanin extracts of purple sweet potato on potassium oxonate-induced hyperuricemia in mice. Phytother Res. 25:1415–1417. 2011.PubMed/NCBI
24	Wang Y and Bao X: Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms. Eur J Med Res. 18:262013. View Article : Google Scholar : PubMed/NCBI
25	Schwartz IF, Grupper A, Chernichovski T, et al: Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. J Vasc Res. 48:252–260. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zharikov SI, Swenson ER, Lanaspa M, et al: Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? Med Hypotheses. 74:1069–1074. 2010. View Article : Google Scholar : PubMed/NCBI
27	Tsai IJ, Croft KD, Puddey IB, Beilin LJ and Barden A: 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. Am J Physiol Heart Circ Physiol. 300:H1194–H1200. 2011. View Article : Google Scholar : PubMed/NCBI
28	Lagerqvist EL, Finnin BA, Pouton CW and Haynes JM: Endothelin-1 and angiotensin II modulate rate and contraction amplitude in a subpopulation of mouse embryonic stem cell-derived cardiomyocyte-containing bodies. Stem Cell Res. 6:23–33. 2011. View Article : Google Scholar : PubMed/NCBI
29	Papageorgiou N, Tousoulis D, Antoniades C, Giolis A, Briasoulis A and Stefanadis C: The impact of statin administration in acute coronary syndromes. Hellenic J Cardiol. 51:250–261. 2010.PubMed/NCBI
30	Doi T, Sakoda T, Akagami T, et al: Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol. 295:H1279–H1287. 2008. View Article : Google Scholar : PubMed/NCBI
31	Takahashi Y, Satoh M, Tabuchi T and Nakamura M: Prospective, randomized, single-blind comparison of effects of 6 months’ treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart Vessels. 27:337–343. 2012.
32	Ali F, Zakkar M, Karu K, et al: Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. J Biol Chem. 284:18882–18892. 2009. View Article : Google Scholar : PubMed/NCBI
33	Lardizabal JA and Deedwania PC: The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep. 13:43–50. 2011. View Article : Google Scholar : PubMed/NCBI
34	Pasceri V, Willerson JT and Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2165–2168. 2000. View Article : Google Scholar : PubMed/NCBI
35	Datar R1, Kaesemeyer WH, Chandra S, et al: Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. Br J Pharmacol. 160:1765–1772. 2010. View Article : Google Scholar : PubMed/NCBI
36	Miyata R, Hiraiwa K, Cheng JC, et al: Statins attenuate the development of atherosclerosis and endothelial dysfunction induced by exposure to urban particulate matter (PM10). Toxicol Appl Pharmacol. 272:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
37	Meda C, Plank C, Mykhaylyk O, Schmidt K and Mayer B: Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells. Pharmacol Rep. 62:100–112. 2010. View Article : Google Scholar : PubMed/NCBI
38	Zhou Q and Liao JK: Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 74:818–826. 2010. View Article : Google Scholar : PubMed/NCBI
39	Yu ZF, Yang C, Qiu X, Chen Y, Kong LD and Wang MS: The influence of daphnin on rats suffering hyperuricemia. Zhongguo Yi Ke Da Xue Xue Bao. 33:142–145. 2002.(In Chinese).